Retrospective survey on the prevalence and outcome of prior autoimmune diseases in patients with aplastic anemia reported to the registry of the European group for blood and marrow transplantation by Cesaro, Simone et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Acta Haematol 2010;124:19–22  
 DOI: 10.1159/000313783 
 Retrospective Survey on the Prevalence and 
Outcome of Prior Autoimmune Diseases in 
Patients with Aplastic Anemia Reported to the 
Registry of the European Group for Blood and 
Marrow Transplantation 
 Simone Cesaro  a    Judith Marsh  b    Gloria Tridello  a    Alicia Rovò  c    Sebastien Maury  d    
Barbara Montante  e    Tamás Masszi  f    Maria Teresa Van Lint  g    Boris Afanasyev  h    
Arturo Iriondo Atienza  i    Marc Bierings  j    Cecilia Carbone  k    Michael Doubek  l    Edoardo Lanino  m    
Mahmoud Sarhan  n    Antonio Risitano  o    Katerina Steinerova  p    Anders Wahlin  q    
Anna Pegoraro  a    Jakob Passweg  r 
 a   Pediatric Hematology Oncology, Department of Pediatrics, University of Padua,  Padua , Italy;  b   Department of 
Haematological Medicine, King’s College Hospital,  London , UK;  c   Department of Hematology, University Hospital, 
 Basel , Switzerland;  d   Department of Hematology, Henri Mondor Hospital,  Créteil , France;  e   Hematology and SCT 
Unit, S. Camillo Hospital,  Rome , Italy;  f   Department of Hematology and Stem Cell Transplantation, St. István and 
St. Laszlo Hospital,  Budapest , Hungary;  g   Department of Hematology II, Ospedale San Martino,  Genoa , Italy; 
 h   Department of Hematology and Transplantology, St. Petersburg State Medical Pavlov University,  St. Petersburg , 
Russia;  i   Department of Hematology, Marqués de Valdecilla University Hospital,  Santander , Spain;  j   Department of
Hematology, University Hospital for Children (WKZ),  Utrecht , The Netherlands;  k   Department of Hematology, 
Spedali Civili,  Brescia , Italy;  l   Department of Internal Medicine, Hematology and Oncology, University Hospital, 
 Brno , Czech Republic;  m   Department of Pediatric Hematology Oncology, G. Gaslini Institute,  Genoa , Italy;  n   King 
Hussein Cancer Centre,  Amman , Jordan;  o   Division of Hematology, ‘Federico II‘ Medical School, University of 
Naples,  Naples , Italy;  p   Department of Hematology/Oncology, Charles University Hospital,  Pilsen , Czech Republic; 
 q   Department of Hematology, Umea University Hospital,  Umeå , Sweden;  r   Department of Internal Medicine, 
University Hospital,  Geneva , Switzerland
 
 Methods: 1,251 AA patients from 18 EBMT centers were as-
sessed.  Results: Fifty patients (4%) were eligible: 22 males 
and 28 females with a median age of 46 years at the diagno-
sis of aID and of 51 years at the diagnosis of AA. Information 
on the treatment of AA was available in 49 patients: 38 re-
ceived only immunosuppressive therapy (IST), 8 patients un-
derwent hematopoietic stem cell transplantation (HSCT) – 6 
as first-line therapy and 2 after failure of IST – whilst 3 pa-
tients had a spontaneous recovery. After a median follow-up 
of 3.19 years, 32 patients were alive, including 7 of the 8 pa-
tients who underwent HSCT. Only 6 of 32 patients who were 
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 Abstract 
 Background: Aplastic anemia (AA) is rarely described after a 
diagnosis of autoimmune disease (aID).  Aims: To assess the 
prevalence of prior aID in patients with AA recorded in the 
registry of the European Group for Blood and Marrow Trans-
plantation (EBMT) and to evaluate treatment and outcome. 
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alive at the last follow-up were receiving IST for AA.  Conclu-
sions: Most cases of AA following aID benefitted from IST or 
HSCT if a matched donor was available. Further prospective 
investigation is needed to assess the effects of IST on the 
outcome of underlying aID.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Aplastic anemia (AA) is caused by an acquired T cell 
immune dysfunction that impairs bone marrow progen-
itor cell function. This results in progressive cytopenia 
and the need for red cell and platelet transfusion. Several 
factors have been advocated as a trigger for the develop-
ment of AA (viral infections, drugs, chemical compounds 
and pregnancy), but recent data highlight the role of dys-
regulation of immune response and of cytotoxic T cells 
expressing Th1 cytokines as effector cells  [1] . Some au-
thors described the occurrence of AA in patients suffer-
ing from autoimmune diseases (aIDs), suggesting that 
AA may be caused by a common dysregulation of im-
mune response in recognizing self-antigens  [2–14] . Re-
cently, Stalder et al.  [15]  found that 13 of 243 patients 
(5.3%) had an aID before the diagnosis of AA and 11 of 
243 patients (4.5%) developed an aID after the diagnosis 
of and treatment for AA. 
 The primary aim of this study was to perform a retro-
spective survey of the prevalence of prior aID in patients 
with AA reported in the registry of the European Group 
for Blood and Marrow Transplantation (EBMT) and to 
evaluate their treatment and outcome. 
 Patients and Methods 
 The study was approved by the scientific committee of the
EBMT-Severe Aplastic Anemia Working Party. Patients were eli-
gible if they had a diagnosis of any aID before the occurrence of 
AA. EBMT participating centers were asked to fill in a case report 
form (MED C form) containing specific information which was 
not evaluable in the EBMT registry database, such as type of aID, 
date of diagnosis, response of the aID to AA treatment and cur-
rent status. Data collection and processing were in accordance 
with EBMT guidelines asking for informed consent, and anony-
mized data-sharing with EBMT. Immunosuppressive therapy 
(IST) was performed according to EBMT guidelines for severe AA 
(SAA)  [16] . 
 The definition of AA and response to treatment were accord-
ing to standard criteria  [17] . Follow-up was up to December 31, 
2008. 
 Results 
 Eighteen EBMT centers from 11 countries agreed to 
participate in the study, identifying 50 patients (Appen-
dix 1). Considering the number of AA patients reported 
by those centers during the study period (n = 1,251), the 
prevalence was 4%. Of these 50 patients, 22 were males 
and 28 were females with a median age of 46 years (range 
9–75) at the diagnosis of aID and of 51 years (range 12–
77) at the diagnosis of AA. 
 The reported diagnosis of aIDs and numbers of affected 
patients were as follows: rheumatic arthritis in 12, psoriasis 
in 5, scleroderma in 4, ulcerative colitis in 4, autoimmune 
hypothyroidism in 4, ankylosing spondylitis in 3, multiple 
sclerosis in 3, systemic lupus erythematosus in 3, Sjögren’s 
syndrome in 2, focal segmental glomerulosclerosis in 2, 
diabetes in 1, dermatitis herpertiformis in 1, pernicious 
anemia in 1, myasthenia gravis in 1, polyangiitis in 1, pri-
mary antiphospholipid syndrome in 1, celiac disease in 1, 
and immune thrombocytopenic purpura in 1. 
 The center investigator judged that in 17 of 50 patients 
(34%), the development of AA was possibly related to 
drugs administered to treat the aIDs, such as gold salts 
in 5, salazopyrine in 4, azathioprine in 3, and in 1 each 
for fenbufen, indomethacin, mesalazine, and carba-
mazepine.
 AA was classified as nonsevere AA (NSAA) in 17 pa-
tients, SAA in 16 patients and very severe (VSAA) in 12 
patients; for 5 patients, the data were not available. 
 Information on the treatment of AA was available in 49 
of 50 patients: 38 received only 1–2 courses of IST, 8 pa-
tients underwent hematopoietic stem cell transplantation 
(HSCT) – 6 as first-line therapy and 2 after failure of IST 
– whilst 3 patients had a spontaneous recovery. The un-
derlying diseases in these patients were as follows: psoria-
sis in 3, rheumatoid arthritis in 2, autoimmune hypothy-
roidism in 1, scleroderma in 1 and diabetes type 1 in 1.
 Table 1 summarizes the type and results of IST. Com-
plete and partial response rates were 37.5 and 22.5%, re-
spectively. Given the different types of aID, the search for 
any potential correlation between the previous underly-
ing disease and the response to IST was not possible. 
 In 26 of 38 patients treated with IST, the center inves-
tigator also recorded the effect of this therapy on the un-
derlying aIDs. IST exerted a clinically beneficial effect on 
the aIDs in 11 patients; in 13 patients, no changes were 
observed whilst 2 patients experienced a worsening of 
their aIDs with their recovery from AA. 
 In the 8 HSCT patients, the donor was related in 6 
cases (5 were siblings) and unrelated in the other 2 cases. 
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These last 2 patients have previously failed the IST with 
cyclosporine and antithymocyte globulin (ATG) whilst 
the first 6 patients received the related allogeneic HSCT 
as first-line treatment of AA. The stem cell source was 
bone marrow and peripheral blood in 4 cases each. Seven 
patients received a nonmyeloablative conditioning regi-
men consisting of 120–200 mg/kg of cyclophosphamide 
 8 ATG or alemtuzumab. Total body irradiation was also 
attempted in 1 of them. One patient received a reduced-
intensity conditioning with cyclophosphamide-fludara-
bine and ATG.
 Outcome: after a median follow-up of 3.19 years (range 
0.2–17), 32 patients were alive, including 7 of the 8 pa-
tients who underwent HSCT. Viral infection was the 
cause of death in the 8th HSCT patient. 
 Three patients were lost to follow-up. Overall, 15 pa-
tients died – 6 of infections, 2 of chronic obstructive pul-
monary disease, 2 of bleeding, and 5 of other unspecified 
causes. Only 6 of 32 patients who were alive at the last 
follow-up were receiving continued IST for AA, either 
with low doses of steroids or androgens. 
 Discussion 
 In this study, we found that 4% of patients recorded in 
the Aplastic Anemia Registry of EBMT had a prior aID. 
This figure confirms that published recently in the single-
center study of Stalder et al.  [15]  in which 5.3% of patients 
with AA had been previously diagnosed and treated for 
AIDs. In that study, this association was more frequent in 
older patients. In line with that observation, the median 
age at diagnosis of aIDs was 46 years in our cohort and 
that of AA 51 years, i.e. a median of 5 years older. 
 Overall, the development of bone marrow failure is a 
not so rare complication in patients with aIDs, and it was 
found in both forms with B cell and T cell dysfunction. 
In contrast to the figures reported by Stalder et al.  [15] , 
female gender was more represented than male gender,
as expected in aIDs. Moreover, previous or concurrent 
rheumatic aIDs were more frequently reported than oth-
er aIDs. In the investigator’s opinion, this can, in part, be 
explained by the fact that in 34% of the cases, bone mar-
row failure was associated with previous treatment with 
drugs that are potentially toxic to marrow stem cells and 
are commonly used in the treatment of rheumatic arthri-
tis. Nevertheless, in the absence of an adequate control 
group, we were not able to elucidate the pathogenic role 
of these therapies. 
 Irrespective of the type of aID and the pathogenesis of 
bone marrow dysfunction, a complete or partial response 
was obtained with IST in more than half of the patients, 
and of note, without a rebound of the aID following IST 
withdrawal, except in 2 cases. In addition, almost one 
third of the patients (11/38) reduced their treatments for 
their aIDs after IST for AA. 
 The type of IST varied among patients, but the most 
successful combination was based on ATG and cyclospor-
ine: 13 of 19 patients treated (68%) obtained complete or 
partial responses. Nowadays, this combination is consid-
ered the standard of care also for all the forms of autoim-
mune/idiopathic bone marrow deficiency (AA, SAA, and 
VSAA) not associated with aIDs. It has been speculated 
that a common cytokine pathway such as that mediated 
Type of treatment Complete
response
Partial 
response
No 
response
Data not 
available
ALS or ATG1 or alentuzumab 3 1 5 1
CSA 11 1
ALS or ATG + CSA 9 4 6
ALS or ATG or CSA + another treatment2 3 2 2
Prednisone with azathioprine or 
cyclophosphamide 1 1
Total 15 (37.5%) 9 (22.5%) 14 (35%) 2 (5%)
A LS = Antilymphocyte serum; ATG = antithymocyte serum; CSA = cyclosporine; 
HSCT = hematopoietic stem cell transplantation.
1 Coupled with plasma exchange.
2 Other treatment: oxymetholone in 3, granulocyte colony-stimulating factor in 3, 
infliximab in 1. 
Table 1.  Results of IST in the 40 patients 
treated (including the 2 patients who 
failed IST before undergoing HSCT)
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by interferon-  secretion may play a role in apparently 
unrelated diseases, such as AA and several aIDs  [6] .
 Interestingly, there were no cases of graft failure fol-
lowing HSCT or uncommon transplantation-related 
mortality; in all cases but 1, HSCT resulted in cure  [9] , 
but we acknowledge that no major conclusions can be 
drawn due to the limited number of patients. 
 In conclusion, in most cases, all the forms of bone 
marrow failure – AA, SAA, and VSAA – following aIDs 
deserve a standard approach with IST using the combina-
tion of ATG plus cyclosporine, or consideration for allo-
geneic HSCT if a sibling-matched donor is available, and 
the patient has SAA. These forms of bone marrow failure 
respond to IST although the pathogenic mechanism is 
not completely elucidated. Considering the limited data 
available and the heterogeneity of IST drugs available, a 
prospective study is needed to assess the effects of IST on 
the final outcome of specific aIDs. 
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 Appendix 1
Investigator CIC State Center Patients
n
Judith Marsh 539 UK London 23
Alicia Rovò 202 Switzerland Basel 6
Simone Cesaro 285 Italy Padua 2
Sebastien Maury 252 France Paris 2
Barbara Montante 287 Italy Rome 2
Maria Teresa Van 
Lint 217 Italy Genoa 2
Tamás Masszi 556 Hungary Budapest 2
Boris Afanasyev 725 Russia St. Petersburg 1
Arturo Iriondo 
Atienza 242 Spain Santander 1
Marc Bierings 239 The Netherlands Utrecht 1
Cecilia Carbone 288 Italy Brescia 1
Michael Doubek 597 Czech Republic Brno 1
Edoardo Lanino 274 Italy Genoa 1
Jakob Passweg 261 Switzerland Geneva 1
Mahmoud Sarhan 580 Jordan Amman 1
Antonio Risitano 766 Italy Naples 1
Katerina Steinerova 718 Czech Republic Pilsen 1
Anders Wahlin 731 Sweden Umeå 1
C IC = EBMT center identification code.
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